Studies in people and in animal models suggest that atorvastatin,
rosuvastatin (Crestor), and simvastatin are associated with elevated risk
for diabetes, whereas pravastatin is associated with lower risk. In this
population-based cohort study, investigators in Canada used administrative
databases to assess incident diabetes between 1997 and 2010 in 471,000
older patients (age, [≥]66) who were newly treated with statins (median
age at treatment onset, 73).
After adjustment for multiple confounders, with pravastatin as the
reference drug, risk for new diabetes was 10%, 18%, and 22% higher in
participants who received simvastatin, rosuvastatin, and atorvastatin,
respectively. Corresponding numbers needed to harm were 363 (simvastatin),
210 (rosuvastatin), and 172 (atorvastatin). Fluvastatin and lovastatin were
not associated with excess risk. Compared with low statin doses
(pravastatin, fluvastatin, and lovastatin at all doses; atorvastatin, <20
mg; rosuvastatin, <10 mg; simvastatin, <80 mg), moderate and high statin
doses were associated with higher diabetes risk.
Comment: In this study, compared with pravastatin, moderate- and
high-potency statins (simvastatin, rosuvastatin, and atorvastatin) were
associated with higher risk for incident diabetes. Using low doses of these
drugs or low-potency statins (fluvastatin and lovastatin) might mitigate
this risk. Notably, these results are biologically plausible: Simvastatin
diminishes insulin secretion, whereas pravastatin improves insulin
sensitivity and inhibits gluconeogenesis.
An editorialist recommends: "When
total cardiovascular risk favours statin treatment, a low dose, low potency
agent should be used to begin with." However, some readers will disagree
and will argue that, for some high-risk patients, benefits of high-potency
statins outweigh the small absolute risk for incident diabetes.
|